Dupilumab
Based on 6 publication(s) in Google Scholar
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.
For research use only. We do not sell to patients.
- Purity: ≥99.2%
- CAS No.: 1190264-60-8
- Molecular Weight:147 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Dupilumab
More- ACS Nano. 2025 Sep 16;19(36):32361-32373. [Abstract]
- Allergy. 2025 Oct 22. [Abstract]
- J Allergy Clin Immunol. 2026 Feb 26:S0091-6749(26)00131-4. [Abstract]
- EBioMedicine. 2022 Sep:83:104200. [Abstract]
- Mucosal Immunol. 2026 Feb 21:S1933-0219(26)00021-8. [Abstract]
- Cytojournal. 2025 Sep 6:22:79. [Abstract]
-
ELISA
-
Cell Imaging/Staining
-
IF
-
RT-PCR
-
Flow Cytometry
Biological Activity
Human IgG4 kappa
Human
|
IL-2 |
IL-4 |
IL-13 |
Dupilumab suppressed mRNA expressions of genes related to activation of T cells, DCs, eosinophils, inflammatory pathways, and TH2-inducing chemokines in skin lesions. No significant reduction in IL-17A or IL-22 levels is detected, but large reductions in expression of IL-17–related genes, such as elafin (PI3), IL23p19/IL23A, and S100A8 and trends for suppression (CXCL1 and S100A7) are found with 300 mg of Dupilumab[1].
Major suppressions of hyperplasia-related genes (eg, K16) and reductions in expression of S100A genes are evident with 300 mg of Dupilumab by using microarrays and qRT-PCR. The changes in other critical epidermal alterations in severe atopic dermatitis (AD) skin are also measured, including significant increases in claudin and lipid product levels with 300 mg of Dupilumab. A trend of dose-dependent increases in expression of differentiation genes (LOR and FLG) is observed after adjusting for suppression of epidermal hyperplasia, as demonstrated by K16 reductions with Dupilumab[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 1190264-60-8
-
Appearance Liquid
-
Molecular Weight 147 kDa
-
Color Colorless to light yellow
-
SMILES
[Dupilumab]
-
Synonyms
REGN-668; SAR-231893
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
ACS Nano
Combining Microfluidic Assessment with Encoded Hydrogel Microparticle-Based Immunoassay for Anti-Interleukin Drug Repurposing of Pulmonary Fibrosis Therapy. [Abstract]2025 Sep 16;19(36):32361-32373. PMID: 40903905
Dupilumab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373. [Abstract]
Dupilumab (5 μg/mL, 48 h). Cytokine concentrations measured in culture supernatants following drug treatments.
Dupilumab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373. [Abstract]
Representative images of spheroids subjected to microfluidic deformation analysis, comparing untreated control, antifibrotic drug NTD, and anti-interleukin drugs TCZ, STX, DUP (Dupilumab; 5 μg/L; 48 h), and TRA.
Dupilumab purchased from MedChemExpress. Usage Cited in: ACS Nano. 2025 Sep 16;19(36):32361-32373. [Abstract]
Confocal fluorescence images showing the expression of collagen-1 and α-SMA in spheroids treated with NTD, TCZ, STX, DUP (Dupilumab, 5 μg/L, 48 h), and TRA.
-
Allergy
Club Cells in Nasal Epithelial Repair: Insights From an IL-13-Induced Inflammatory Model. [Abstract]2025 Oct 22. PMID: 41123053
Dupilumab purchased from MedChemExpress. Usage Cited in: Allergy. 2025 Oct 22. [Abstract]
Comparison of mRNA levels for SCGB1A1, FOXJ1, and MUC5AC in untreated, IL-13, AS1517499, and Dupilumab (10 μM, 6 h)-treated HNECs using RT-qPCR.
Dupilumab purchased from MedChemExpress. Usage Cited in: Allergy. 2025 Oct 22. [Abstract]
Dupilumab (10 μM, 6 h). Flow cytometry analysis of changes in SCGB1A1+βIVtubulin and SCGB1A1+MUC5AC+ clusters across treatment groups.
-
J Allergy Clin Immunol
Eosinophilic chronic rhinosinusitis with nasal polyps: Squamous metaplasia as an associated remodeling feature. [Abstract]2026 Feb 26:S0091-6749(26)00131-4. PMID: 41759748 -
EBioMedicine
Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via suppressing M2 macrophages polarization. [Abstract]2022 Sep:83:104200. PMID: 35932642 -
Mucosal Immunol
Interaction between airway basal cells, mast cells and type 2 immunity contributes to epithelial barrier dysfunction in allergic rhinitis. [Abstract]2026 Feb 21:S1933-0219(26)00021-8. PMID: 41730474 -
Cytojournal
2025 Sep 6:22:79. PMID: 41216237
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)